In conclusion, SFX-01 inhibits Shp2 through a novel covalent dithiolethione modification, enabling selective targeting of disease-associated mutant variants while exhibiting therapeutic efficacy in preclinical models of NS or in human JMML cells. Here, PTPN11 is linked to juvenile myelomonocytic leukemia.